Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer

Nor Hasymah Haron1,2, Ezanee Azlina Mohamad Hanif2, Mohd Rizal Abdul Manaf3, Jasmi Ali Yaakub4, Roslan Harun2, Ramelah Mohamed2, Isa Mohamed Rose1*

Abstract

Introduction: Microsatellite instability (MSI) is a hallmark of defective DNA mismatch repair (MMR) of genes especially MLH1 and MSH2. It is frequently involved in the carcinogenesis of various tumours including gastric cancer (GC). However, MSI in GCs have not been reported in Malaysia before. Objective: This study was conducted to determine the microsatellite instability (MSI) status in gastric cancer by microsatellite analysis, sequencing, its association with MLH1 and MSH2 protein expression and H. pylori infection by immunohistochemistry. Method: A total of 60 gastric cancer cases were retrieved. DNA was extracted from paired normal and tumour tissues while MLH1 and MSH2 protein expression as well as H. pylori status were determined by IHC staining. For microsatellite analysis, polymerase chain reaction (PCR) was performed for paired tissue samples using a panel of five microsatellite markers. MSI-positive results were subjected for DNA sequencing to assess mutations in the MLH1 and MSH2 genes. Results: Microsatellite analysis identified ten MSI positive cases (16.7%), out of which only six cases (10.3%) showed absence of MLH1 (n=3) or MSH2 (n=3) protein expression by IHC. The most frequent microsatellite marker in MSI positive cases was BAT26 (90%). Nine of ten MSI positive cases were intestinal type with one diffuse and all were located distally. H. pylori infection was detected in 13 of 60 cases (21.7%) including in three MSI positive cases. All these results however were not statistically significant. Our sequencing data displayed novel mutations. However these data were not statistically correlated with expression levels of MLH1 and MSH2 proteins by IHC. This may be due to small sample size to detect small or moderately sized effects. Conclusion: The frequency of MSI in this study was comparable with published results. Determination of affected MMR genes by more than two antibodies may increase the sensitivity of IHC to that of MSI analysis.

Keywords: Gastric cancer- microsatellite instability- immunohistochemistry- microsatellite analysis

Asian Pac J Cancer Prev, 20 (2), 509-517

Introduction

Previous studies evidently showed 4 distinct subtypes of GCs; one with high infection of Epstein-Barr virus, microsatellite instability that leads to high hypermethylation status in MLH1 gene, genomic instability in diffused GC histology, and chromosomal instability with vast numbers of somatic copy number aberrations mostly in intestinal histological types of GCs (Wong et al., 2015). Microsatellite instability (MSI) accounted for 13-44% of GCs depending on the number of cases and remains as the hallmark of GCs (Moskaluk and Rumpel, 1998; Wirtz et al., 1998). A panel of five microsatellite markers (NCI panel) were recommended by National Cancer Institute in 1997 to provide some uniformity in defining MSI positive tumours in colorectal cancer (Boland et al., 1998).

However, the efficiencies of these markers associated with extracolonic cancers including GC remains uncertain and need to be evaluated.

Microsatellite instability is a resultant of defective DNA mismatch-repair (MMR) genes including hMSH2, hMLH1, PMS1, PMS2, hMSH6 and hMSH3. Germline mutations of hMLH1 and hMSH2 are among the most frequently found in hereditary nonpolyposis colon carcinoma (HNPPC) or Lynch Syndrome (Han et al., 1995). Microsatellite instability refers to changes in at least a single to two or more nucleotide repeat segments known as microsatellites that are distributed throughout the genome (Ionov et al., 1993).

GC with presence of MSI is associated with certain clinicopathological characteristics such as older age of presentation, distal tumour location, intestinal type

1Department of Pathology, 2UKM Medical Molecular Biology Institute (UMBI), 3Department of Community Health, University Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, 56000 Cheras, Kuala Lumpur; 4General Surgery, KPJ Ampang Puteri Specialist Hospital, No. 1 Jalan Mamanda 9, Taman Dato Ahmad Razali, 68000 Ampang, Selangor Darul Ehsan, Malaysia.
*For Correspondence: isa@ppukm.ukm.edu.my
by Laurén classification, expanding type by Ming classification, no lymph metastasis, early disease staging, and better overall prognosis (Lee et al., 2002; Falchetti et al., 2008; Kim et al., 2011). Furthermore, a positive correlation between the presence of *H. pylori* seropositivity and MSI GCs have been observed (Simpson et al., 2000; Scartozzi et al., 2004). Active *H. pylori* infection is present more frequently in individuals carrying MSI GCs, suggesting that *H. pylori* may affect MMR system during the stepwise progression of gastric carcinogenesis.

In Malaysia, 82% GC cases were detected in the late stage (stage IV) and about 16% were detected in early stage (Stage I and II) (Kandasami et al., 2003). More recent data from the Malaysia Cancer Statistics – Data and Figure 2007 report showed almost similar figures of 73.4% of cases detected in Stages III and IV. This situation has drawn attention to the late detection of cancer as an important negative factor in the Malaysian setting. Additionally, limited research has been conducted in exploring the background of GC genetics in Malaysia. The findings of this study could add on to the existing knowledge linked to GCs. This retrospective study intended to determine the frequency of MSI in 60 cases of resected GCs using immunohistochemical expression of MLH1 and MSH2 protein and comparing it with PCR-based MSI analysis using a panel of five MSI markers. MSI positive cases were also screened for mutations to see whether there is any strong correlation with MSI status, *H. pylori* status, MLH1 and MSH2 expressions in GCs.

## Materials and Methods

### Patients and Tissue Samples

Matched pairs of formalin-fixed, paraffin embedded normal and tumour tissue samples were obtained from 60 cases of resected gastric carcinoma from the UKM Medical Centre (UKMMC) following approval from the Ethics Committee of UKMMC. Normal samples were obtained from the matched adjacent GC samples on different FFPE blocks. None of the cases had a sporadic or familial history suggestive of HNPCC syndrome. The clinical information was obtained from pathology reports. A pathologist was referred for the purpose of histopathology diagnoses verification. In total, 39 males and 21 females consisted of 44 Chinese, 14 Malays and 2 Indians were included. The patients were between 28 to 83 years (mean age 64 years). There were 38 intestinal and 22 diffuse cancers confirmed by the Laurén classification. Hematoxylin and eosin–stained (H&E) sections of paraffin blocks were examined, and representative samples were selected for further analysis. 5µm of representative samples were sectioned and laid on coated poly-l-lysine (Sigma Aldrich, St. Louise, USA) slides for immunohistochemical analysis. Approximately, 2 – 10 µm sections from normal and tumour blocks were subjected for DNA isolation using ‘QIAamp DNA Mini Kit’ (QIAGEN, GmbH, Germany).

Publically available data

Survival rate of MLH1 and MSH2 expression levels by Kaplan Meier Plotter Database.

Survival curves were generated from the Kaplan Meier Plotter (Gastric Cancer) database based on the expression levels of the MLH1 and MSH2 from publically available data of 1,065 GC patients. Graphs were generated by taking into account all types of treatments (surgery only, 5-fluorouracil adjuvant and other adjuvant chemo), HER2 status, all stages (TNM), Lauren classification (Intestinal, diffuse and mixed), Differentiation (well, moderate and poor), and gender as selection criteria (Szász et al., 2016).

### Immunohistochemical Staining of MMR proteins (hMLH1, hMSH2) and *H. pylori*

Mouse monoclonal antibodies against hMLH1 (BD Pharmingen, USA) and hMSH2 (Calbiochem, USA) with a dilution factor at 1:50 and 1:150 were used for immunostaining. The immunostaining was performed with Envision Horseradish peroxidase kit (DakoCytomation, Denmark) for hMLH1 and RealTM EnVisionTM Detection Kit (Lab Vision Corporation, Canada, USA) for hMSH2. Diaminobenzidine (DakoCytomation, Denmark) was used as a chromogen. Sections were lightly counterstained with hematoxylin (JT Baker, Holland) for 30 seconds. Absence of MSI was determined by a brownish nucleus staining with DAB. Loss of hMSH2 or hMLH1 expression in cancer tissues was demonstrated by undetectable nuclear staining of neoplastic cells indicated the genes were affected.

### Analysis of MSI

MSI was detected using the National Cancer Institute (NCI) panel of 5 microsatellite markers; BAT25, BAT26, D2S123, D5S346 and D17S250 in normal and tumour tissues. Primer sequences were as described previously (Loukola et al., 2001) and each sense primers were end-labeled with fluorescent marker, Hex. This process was performed by PCR in a total volume of 25 µl consisted of 150-300 ng DNA, 12.5 µl ImmoMixTM (Bioline, UK), and 1 x sense and antisense primers each. PCR amplification was conducted on MyCycler thermocycler (Biorad, USA). Samples were denatured at 95°C for 7 minutes, followed by 40 cycles of denaturation (94°C for 1 minute), annealing (55°C for 1 minute), extension (72°C for 1 minute) and ultimately by final extension at 72°C for 7 minutes and were kept hold at 4°C. Then, 1µl of fluorescently labeled PCR products was mixed with 12µl deionized formamide and 1µl GeneScan TAMRA 500 Size Standard (Applied Biosystem, Carlsbad, CA, USA). The mixture was denatured at 94°C for 5 minutes and hold at 4°C before loaded to the ABI PRISM 3130XL Genetic Analyzer (Applied Biosystem).

The data was analysed using Gene Mapper software (Applied Biosystems), which automatically determined the actual size of PCR products and the amount of fluorescent signal from electropherograph outputs. MSI was predicted by the presence of novel peaks in tumour tissue compared to control. The second indicator for MSI was the difference in microsatellite length in these samples. Tumours exhibited MSI with two or more markers were defined as MSI positive.
Sequencing

Samples that displayed positive MSI were subjected for direct sequencing. The DNA samples were set up for sequencing using BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) consisted of 2 µl BigDye buffer, 1.6 µl Sequencing primer, 0.2 µl BigDye Enzyme and 100 ng DNA. Sequencing cycle condition was set up accordingly on Genetic Analyzer (Applied Biosystems).

Statistical Analysis

The sensitivity and specificity of MLH1 or MSH2 immunostaining in identifying MSI positive tumours were calculated. Sensitivity was defined as the absence of MLH1 or MSH2 expressions by IHC in MSI positive tumours, while specificity was defined as intact expressions of MLH1 and MSH2 by IHC in MSI negative tumours. Tests for differences between MSI positive and MSI negative groups were performed using either the chi-square test or the Fisher’s exact test. P value ≤ 0.05 were considered to be statistically significant.

Results

MLH1 and MSH2 expression levels are associated with poor survival in gastric cancers

Survival curves of MLH1 and MSH2 were generated from the KM-plotter database, showed significant poor overall survival in high MLH1 and MSH2 expressions. This indicated that these markers might represent as a good prognostic value in GCs.

Microsatellite Instability

Ten cases (10/60, 16.7%) showed MSI positive by microsatellite analysis. Out of which only six cases (10.3%) showed absence of protein expression, three by loss of MLH1 (Figure 2A) and three by MSH2 (Figure 2B) via immunostaining. The rest 50 cases (83.3%) were considered MSI negative. The sensitivity and specificity rates for IHC testing assessed against MSI positive results were 60% (6 of 10) and 100% (50 of 50) respectively. The most frequently positive of the panel markers was BAT26 (90%) whilst the rest D17S250, BAT25, D5S346 and D2S123 being 60%, 50%, 30% and 20% respectively. Figure 3 showed an example of electropherogram reading from Genotyper Analysis Software (Applied Biosystems) for a case with MSI positive. This case showed instability for BAT25 and BAT26 markers. Table 1 showed comparison of microsatellite analysis with MSH2 and/or MLH1 immunohistochemical staining. There were four MSI positive cases with intact MLH1 and MSH2 protein expressions. Table 2 displayed clinicopathological characteristics of ten MSI positive cases, involving eight Chinese (six males and two females) and two Malay females. Of the ten MSI positive cases, nine were of intestinal type and one diffuse. H. pylori infection was detected in normal gastric mucosa in 13 of 60 cases (21.7%) including three MSI positive cases by IHC (Table 3). However, all these results were statistically insignificant (Table 3).

Mutations in the MLH1 and MSH2 genes are negatively correlated with protein expression

DNA sequencing analyses presented 13 and 9 mutations, in both MLH1 and MSH2 respectively. Amongst the detected mutations, only one mutation was previously reported flanking the 12B intronic region

Table 1. Comparison of Microsatellite Analysis with MSH2 and/or MLH1 Immunohistochemical Finding. Mismatch Repair Defective Tumours are Those Carcinomas Exhibited Loss of Either MLH1 or MSH2 Expressions by Immunohistochemistry.

| IHC          | MSI negative | MSI positive | Total |
|--------------|--------------|--------------|-------|
| MLH1 and MSH2 present | 50           | 4            | 54    |
| MLH1 loss    | 0            | 3            | 3     |
| MSH2 loss    | 0            | 3            | 3     |

Figure 1 Disease Free Survival of Gastric Cancer Patients in Association with Transcriptomic MLH1 and MSH2 Expression Levels. (A) High MLH1 expression is significantly associated with worst overall survival in gastric cancer patients (HR = 1.43; p-value = 0.00069). Inverse correlation observed in high MSH2 gene expression displaying good overall survival in gastric cancer patients (HR = 0.58; p-value = 7.6e-08).
of the MLH1 (Case 15) while others were uniquely observed in this current study and never been reported in any other Lynch Syndrome studies as denoted in the MMR Genes Variance Database, International Society for Gastrointestinal Hereditary Tumours Database and Human Gene Mutation Database suggesting that these mutations are novel mutations. Our sequencing data noted mutation of G to A nucleotide substitution at region c.1409+1. This mutation was also reported in a single nucleotide polymorphism database (http://www.

| Case no. | Type*     | Age | Ethnic | Stage            | Microsatellite markers | IHC |
|---------|-----------|-----|--------|------------------|------------------------|-----|
|         |           |     |        |                  | BAT25 | BAT26 | D2S123 | D5S346 | D17S250 | MSH2 | MLH1 |
| 2       | Intestinal| 67  | Chinese| -**             | -     | +     | -      | -      | +       | -    | +    |
| 15      | Intestinal| 83  | Chinese| -**             | +     | +     | -      | -      | -       | +    | +    |
| 21      | Diffuse   | 65  | Chinese| Advanced stage  | -     | +     | -      | -      | -       | +    | -    |
| 27      | Intestinal| 73  | Chinese| Stage IV       | -     | +     | -      | +      | +       | +    | -    |
| 28      | Intestinal| 63  | Chinese| Stage IIIA     | +     | +     | -      | +      | -       | +    | -    |
| 30      | Intestinal| 69  | Chinese| Stage IB       | +     | +     | -      | -      | +       | +    | -    |
| 35      | Intestinal| 55  | Chinese| Stage IIB      | -     | +     | -      | +      | -       | +    | -    |
| 37      | Intestinal| 79  | Malay  | Stage III      | -     | -     | +      | -      | +       | +    | +    |
| 41      | Intestinal| 54  | Malay  | Stage IIB      | +     | +     | -      | -      | +       | +    | +    |
| 46      | Intestinal| 64  | Chinese| Stage IIIA     | +     | +     | -      | -      | +       | +    | -    |

Table 2. Clinicopathological Characteristics for MSI Positive Cases

| Variable       | n  | MSI negative (n = 50) | MSI positive (n = 10) | P*  |
|----------------|----|-----------------------|-----------------------|-----|
| Age            |    |                       |                       | 0.183|
| < 50 years     | 11 | 11                    | 0                     |
| ≥ 50 years     | 49 | 39                    | 10                    |
| Sex            |    |                       |                       | 1   |
| Male           | 38 | 32                    | 6                     |
| Female         | 22 | 18                    | 4                     |
| Type (Laurèn)  |    |                       |                       | 0.146|
| Intestinal     | 39 | 30                    | 9                     |
| Diffuse        | 21 | 20                    | 1                     |
| Lymph node spread|    |                       |                       | 1   |
| Absent         | 16 | 13                    | 3                     |
| Present        | 44 | 37                    | 7                     |
| Race           |    |                       |                       | 0.651**|
| Malay          | 14 | 12                    | 2                     |
| Chinese        | 44 | 36                    | 8                     |
| Indian         | 2  | 2                     | 0                     |
| Sites          |    |                       |                       | 0.334***|
| Distal         | 50 | 40                    | 10                    |
| Proximal       | 9  | 9                     | 0                     |
| Anastomotic    | 1  | 1                     | 0                     |
| H. pylori      |    |                       |                       | 0.675|
| Absent         | 47 | 40                    | 7                     |
| Present        | 13 | 10                    | 3                     |

Table 3. Correlation of MSI with Clinicopathological Features

* P values correspond to two-sided Fisher’s exact test; **, Analysis involving Chinese and non-Chinese; ***, Analysis involving tumour located at distal and proximal sites.

Figure 2. (A), Well differentiated intestinal type gastric cancer with positive MSI showing total loss of MLH1 protein expression in tumour cells (T). Normal gastric glands (N) as internal control showing positive staining; (B), Diffuse type gastric cancer with positive MSI showing negative staining for MSH2 protein in tumour cells (T). Stromal cells (S) with positive staining as internal control. (x 200 magnification)
ncbi.nlm.nih.gov/sites/varvu) except for the mutation of Gly706Gly at exon 19 c.2118 of the MLH1 gene (Case 27). This silent mutation displayed changes of the single variant involving changes of C to T nucleotide. Altogether, the 5 novel mutations were located within the conserved domain regions of the Racemase-4 Superfamily and P-loop_NTPase superfamily (Table 4). Our sequencing data indicated all missense mutations detected were not pathogenic based on Pmut software (http://mmb.pcb.ub.es:8080/Pmut) indicating the mutations were not deleterious. A single missense mutation case is pathogenic involving exon 16 with negative expression of MLH1 protein.

Interestingly, our data exhibited a novel frameshift mutation noting deletion of a cytosine at exonic region c.1048 (c.1048delC) flanking exonic region 12A of the MLH1 gene. This mutation was positively correlated with MSI positivity, overexpression of MLH1 protein and was

| Case | Intron/exon | DNA sequence changes | Amino acid changes | Conserved domain region | Mutation type | Pathogenicity | IHC* |
|------|-------------|----------------------|--------------------|-------------------------|---------------|---------------|------|
| 15   | Intron 3    | c.208-47delA         | None               | Deletion                |               |               | Positive |
| 27   | Intron 8    | c.677+72T>G          | None               | Insertion               |               |               | Positive |
| 15   | Exon 9      | c.757G>A             | p.Val253Met        | None                    | Missense      | Neutral/NN: 0.2409 | Negative |
| 15   | Exon 12A    | c.1048delC           | None               | Frameshift              |               |               | Positive |
| 27   | Exon 12B    | c.1227G>A            | p.Gln409Gln        | None                    | Silent        |               | Negative |
| 15   | Exon 13     | c.1464G>A            | p.Lys488Lys        | None                    | Silent        |               | Negative |
| 15   | Exon 16     | c.1732+43G>C         | None               | Insertion               |               |               | Positive |
| 30   | Exon 16     | c.1874A>C            | p.Tyr625Ser        | None                    | Missense      | Pathogenic/NN: 0.6626 | Negative |
| 27   | Exon 19     | c.2118C>T            | p.Gly706Gly        | None                    | Silent        |               | Negative |

Table 5. List of MSI Positive MSH2 Mutation in Gastric cancer. *Immunohistochemistry Status for MSH2

| Case | Intron/exon | DNA sequence changes | Amino acid changes | Conserved domain region | Mutation type | Pathogenicity | IHC* |
|------|-------------|----------------------|--------------------|-------------------------|---------------|---------------|------|
| 21   | Exon 2      | c.214G>A             | Ala72Thr           | None                    | Missense      | Neutral/NN: 0.1368 | Negative |
| 46   | Intron 9    | c.1510+31insAA       | MutS-I             | Insertion               |               |               | Negative |
| 35   | Intron 13   | c.2210+17G>C         | None               | Insertion               |               |               | Negative |
| 15   | Exon 13     | c.208G>A             | Gly637Glu          | P-loop_NTPase superfamily | Missense | Pathogenic/NN: 0.7651 | Positive |
| 15   | Exon 14     | c.2260A>G            | Thr754Ala          | P-loop_NTPase superfamily | Missense | Neutral/NN: 0.1280 | Positive |
| 41   | Intron 14   | c.2209-26G>T         | None               | Insertion               |               |               | Positive |
| 2    | Intron 16   | c.2635-25A>C         | None               | Insertion               |               |               | Negative |
| 35   | Intron 16   | c.2635-25A>C         | None               | Insertion               |               |               | Negative |
positive with H. pylori UreA gene marker (data not shown). However, clinicopathological data was insufficient to associate these variables that could link this mutation to the disease.

The MSH2 also displayed novel mutations harbouring at highly conserved region MutS-IV superfamily with negative expression of MSH2 protein (Table 5). Inverse correlation was observed denoting the c.326A>C missense mutation (Case 46) also located in the MutS-IV conserved region with positive expressions of MSH2. However, this mutation is neutral suggesting it was non-pathogenic. One positively stained MSH2 protein displayed positive correlation with c.2018A>G missense mutation flanking the P-loop_NTPase superfamily conserved region and was pathogenic.

**Discussion**

A variety of techniques have been used for identification of tumours with mismatch repair (MMR) deficiencies ranging from PCR-based to immunohistochemistry (Fidalgo et al., 2000; Samimi et al., 2000). In this study, we combined these techniques to test its specificity to the determination of markers as well as whether the protein expression of the MLH1 gene and MSH2 are highly associated with mutations or whether the MSI may be contributed by mutations of the MLH1 and MSH2 genes. Immunohistochemistry was a complementary method for PCR-based where analysis for the DNA MMR proteins such as MLH1, MSH2, MSH6 and PMS2 are readily available on a clinical basis. IHC also provides information on the specific defective MMR gene involved and may be cost effective by limiting the number of genes to be sequenced to identify individual at risk. PCR-based method may detect cases that have abnormalities in any MMR genes (except certain cases of MSH6 gene defect) including those that are not covered by the IHC antibody panel (Frayling et al., 2005; Shia, 2008).

In this study, sensitivity of IHC testing against microsatellite positive results was slightly low due to four additional MSI positive cases showed intact MLH1 and MSH2 protein expressions. A similar false positive result by immunohistochemistry has been previously reported by other studies which utilised two antibodies in the assessment of MSI analysis (Cai et al., 2004; Modica et al., 2007). This may be due to low sensitivities of IHC staining of both MLH1 and MSH2 antibodies than MSI testing in determining MMR gene defect. However, by taking into account PMS2 and MSH6 staining could significantly increased the sensitivity of IHC resulting an equivalent value to that of MSI testing (Jong et al., 2004; Hampel et al., 2005; Southey et al., 2005). This may be due to heterodimers formation of MMR proteins that in their functional state MSH2 dimerizes with MSH6 to form functional complex MutS-α, while MLH1 dimerizes with PMS2 to form MutL-α. MSH2 and MLH1 proteins were the obligatory partners of their respective heterodimers. Their abnormalities can result in proteolytic degradation of their dimer and consequent loss of both the obligatory and secondary partner proteins. However, if the functions of MSH6 and PMS2 were affected, it does not contribute to concurrent loss of MSH2 and MLH1 protein as the function of the secondary proteins may be compensated by other proteins, such as MSH3, MLH3 and PMS1 (Shia,
In addition, gene abnormalities in MLH1 and MSH2 may cause pathogenic mutations contributed to retained protein expression. This is due to the mutation itself that did not promote protein degradation or truncation, but missense mutation exhibited no difference with wild type polypeptides. Moreover, false positive staining for MLH1 can occur with protein truncating mutations and large in frame deletions in MLH1, where the mechanism is still unclear (Shia, 2008). The inclusion of the two antibodies had the capabilities to detect most abnormalities in MLH1 and MSH2 genes in addition to the mutation detection in MSH6 and PMS2 genes.

Our study showed low frequency of MSI positive GCs closely related to previous studies using the five NCI panels of markers (Fang et al., 2003; Zaky et al., 2008). The clinicopathological characteristics features associated with MSI positive tumours were advanced age of patients, distally located tumours and better overall prognosis (Hayden et al., 1997; Oliveira et al., 1998; Wu et al., 1998). However, insignificant results were obtained between MSI positive and negative group in this study. But, MSI positive tumours were more frequently located at the distal of the stomach and most of them were intestinal type by Laurén classifications and these observations are in line with previous study displayed MSI-H groups that represented loss of MMR proteins and associated with intestinal type. This also indicated its association with overall good prognosis (Karpinska-Kaczmarczyk et al., 2016). However, these data warrant a larger number of GCs samples for further evaluation to elucidate distinct prognosis between MSI tumours and clinicopathological characteristics.

_H. pylori_ status have been used to classify GC subtypes and also indicates the risk and prognostic factors of gastric carcinoma. In this study, _H. pylori_ was determined by IHC staining. The prevalence of _H. pylori_ infection by IHC staining was higher in Chinese (12/13, 92.3%) compared to Malay (1/13, 7%). This result concurred the outcome of GCs itself which is high in Chinese compared to the Malay and Indian in this study as well as the incidence reported in cancer registries from Malaysia (Zainal and Nor Saleha, 2011) and Singapore (Curado et al., 2007).

Previous studies have shown a significant association between GCs with MSI positive and _H. pylori_ infection (Wu et al., 1998; Leung et al., 2000; Li et al., 2005) but some discovered inverse correlation between the two indicators of GCs (Lin et al., 1995; Kashiwagi et al., 2000; Rugge et al., 2005). In this study, three MSI positive were found in 13 patients with _H. pylori_ infection without positive correlation between them. Overall, the association between the _H. pylori_ infection and MSI positive remain unresolved among researchers (Kashiwagi et al., 2000). A recent review suggesting that _H. pylori_ infection act as a synergistic factor in GCs but not a direct factor causing carcinogenesis by altering the gene expression (Shokal and Sharma, 2012). It has been shown that _H. pylori_ infection was infrequently detected in a larger cohort of GCs, which successfully classified four distinct GCs subtypes. This data by TCGA proposed that GC was subdivided into those of which had Epstein-Barr virus infection with lacking hypermethylation status of the MLH1 gene (Matsusaka et al., 2011; Wong et al., 2015). Another subtype was denoted as those having MSI resulted in hypermutated tumours and high hypermethylation status at the MLH1 promoter regions. Genome instability and chromosomal instability were also denoted as GC subtypes affecting the diffuse and intestinal GCs (Wong et al., 2015). Inverse outcomes were seen in another study displayed no correlation of MSI status in each of the classified subtypes (Cristescu et al., 2015). Hence, the urgency in determining the right molecular markers and driver mechanisms in GCs is crucial for improvement of the GC management.

BAT26 is a mononucleotide marker harbour specificities and sensitivity in identifying MSI positive GC (Halling et al., 1999; Guo et al., 2001; Falchetti et al., 2008). Nine over ten GCs showed MSI positive cases by this marker. This might be due to the quasimonomorphic profile (shift of allele is greater than 0 but less than 1 base pair) of BAT26 that amplifies at higher efficiency than the larger normal allele (Brennetot et al., 2005). However, BAT26 should not be solely depended on (Halling et al., 1999). First, it was inadequate to only assess the level of MSI (Bacani et al., 2005; Zaky et al., 2008) and displayed variable electrophoretic patterns in certain cases. Second, it will overestimate the MSI positive phenotype (Bacani et al., 2005). Apart from that, sensitive markers identifying MSI were reported to have different results in different populations (Buhard et al., 2006). Therefore, markers selection should be carefully made when analyses are performed in people with different geographic and genetic backgrounds (Sepulveda et al., 1999).

Studies lately have shown that there is an equivalent sensitivity between IHC and MSI analysis in determining MMR gene abnormalities (Jong et al., 2004; Hampsel et al., 2005; Southey et al., 2005). In this study, however determining affected _MMR_ genes by IHC using MLH1 and MSH2 antibodies may lead to false negative MSI. It has been shown that PCR-based MSI detection was relatively low in GC, however higher prevalence of MLH1 and PMS2 were observed (Karpinska-Kaczmarczyk et al., 2016; Mathiak et al., 2017). Therefore, four antibodies panel (MLH1, MSH2, PMS2 and MSH6) are compulsory panel markers for further evaluation in order to increase sensitivity of IHC as predictive value that is almost equivalent to that of MSI analysis.

Mutations detected in this study was positively correlated with MSI positive but displayed indecisive patterns of _MLH1_ and _MSH2_ expression levels even when the mutations fall within the exonic regions with high pathogenic effect (Table 4 and 5). This scenario may be associated with hypermethylation of the _MLH1_ and _MSH2_ promoter region that represses the expressions of these genes as seen in endometrial cancer with HNPCC syndrome (Chadwick et al., 2001). It was also clear that high MLH1 and MSH2 expressions represented worst survival in GC suggesting high intratumoural heterogeneity within the tumour samples that contributed in GC treatment resistance. Nevertheless, other mutations were rather novel in this study, hence, further assessments of its functional roles is fully recommended to further explicate its prognostic values in GCs. As previously mentioned, MSI status varies greatly in different backgrounds.
population and ethnicity. It would be of a great value then to have higher number of samples to assess the different groups of GCs (intestinal, diffuse and mixed) and the stages to observe strong correlations of the clinical data and genomic instability to rule out surrogate markers to rule out prognosis for novel therapeutic intervention in GCs.

In conclusion, the prevalence of MSI in GC was 16.7% involving mainly intestinal type cancers with all distally located and this compares well with published results. Based on recent work of MMR gene abnormalities detection, four antibodies panel (MLH1, MSH2, PMS2 and MSH6) should be utilised instead of two (MLH1 and MSH2) in order to increase sensitivity of IHC result as a potential predictive value. This detection method has equivalent to that of MSI analysis. Having said that, larger cohorts are required to have a statistically significant profiles of GCs in Malaysia.

Funding
This work was supported by an Intensification Research Priority Area (IRPA) Grant (No. 06-02-02-0057-PR-0073/05-04) from the Ministry of Science and Technology, Malaysia.

Conflict of interest statement
No conflicts of interest were disclosed throughout the study.

Acknowledgements
We would like to thank Mrs. Suzailin Elfrida Abdul Halim and Mrs. Nadiatul Ikmal Alias for their technical supports, the staff of Histopathology Unit and UMBI for their permission and helpful guidance to use all the facilities in order to complete this work.

References
Bacani J, Zwingerman R, Di Nicola N, et al (2005). Tumor microsatellite instability in early onset gastric cancer. J Mol Diagnostics, 7, 465–77.
Boland CR, Thibodeau SN, Hamilton SR, et al (1998). A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: Development of International Criteria for the Determination stability in colorectal Cancer for the Determination of Microsatellite Instability. Interpreted A J Bible Theol, 58, 5248–57.
Bremetot C, Buhard O, Jourdan F, et al (2005). Mononucleotide repeats BAT-26 and BAT-25 accurately detect MSI-H tumors and predict tumor content: Implications for population screening. Int J Cancer, 113, 446–50.
Buhard O, Cattaneo F, Yick FW, et al (2006). Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol, 24, 241–51.
Cai KQ, Albarracin C, Rosen D, et al (2004). Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol, 35, 552–9.
Chadwick RB, Pyatt RE, Niemann TH, et al (2001). Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma. J Med Genet, 38, 461-6.
Cristescu R, Lee J, Nebozhyn M, Kim K-M, et al (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med, 21, 449–56.
Curado MP, Edwards B, Shin HR, et al (2007). Cancer Incidence in Five Continents, Volume VI.
Falchetti M, Saieva C, Lupi R, et al (2008). Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol, 39, 925–32.
Fang DC, Wang RQ, Yang SM, et al (2003). Mutation and methylation of hMLH1 in gastric carcinomas with microsatellite instability. World J Gastroenterol, 9, 655–9.
Fidalgo P, Almeida MR, West S, et al (2000). Detection of mutations in mismatch repair genes in Portuguese families with hereditary non-polyposis colorectal cancer (HNPPC) by a multi-method approach. Eur J Hum Genet, 8, 49–53.
Frayling IM, Happerfield L, Mattocks C, et al (2005). Application of molecular diagnostics to hereditary nonpolyposis colorectal cancer. In Molecular Diagnostics: For the Clinical Laboratorian, W.B. Coleman, and G.J. Tsongalis, eds. (Totowa, NJ: Humana Press), pp 375–92.
Guo RJ, Anai H, Kitayama Y, et al (2001). Microsatellite instability of papillary subtype of human gastric adenocarcinoma and hMLH1 promoter hypermethylation in the surrounding mucosa. Pathol Int, 51, 240–7.
Halling KC, Harper J, Moskaluk CA, et al (1999). Origin of microsatellite instability in gastric cancer. Am J Pathol, 155, 205–11.
Hampel H, Frankel WL, Martin E, et al (2005). Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer). N Engl J Med, 352, 1851–60.
Han HJ, Maruyama M, Baba S, et al (1995). Genomic structure of human mismatch repair gene, hMLH1, and its mutation analysis in patients with hereditary non-polyposis colorectal cancer (HNPPC). Hum Mol Genet, 4, 237–42.
Hayden JD, Cawkwell L, Quirke P, et al (1997). Prognostic significance of microsatellite instability in patients with gastric carcinoma. Eur J Cancer, 33, 2342–6.
Ikonov Y, Peinado MA, Malkhosyan S, et al (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature, 363, 558–61.
Jong AE De, Puijenbroek M Van, Hendriks Y (2004). Additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. In Molecular Diagnostics: For the Clinical Laboratorian, W.B. Coleman, and G.J. Tsongalis, eds. (Totowa, NJ: Humana Press), pp 375–92.
Kandasami P, Tan WJ, Norain K (2003). Gastric cancer in Malaysia: The need for early diagnosis. Med J Malaysia, 58, 758–62.
Karpinska-Kaczmarczyk K, Lewandowska M, Lawnickzak M, et al (2016). Expression of mismatch repair proteins in early and advanced gastric cancer in Poland. Med Sci Monit, 22, 886-92.
Kashiwagi K, Watanabe M, Ezaki T, et al (2000). Clinical usefulness of microsatellite instability for the prediction of gastric adenoma or adenocarcinoma in patients with chronic gastritis. Br J Cancer, 82, 1814–8.
Kim H, An JY, Noh SH, et al (2011). High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol, 26, 585–92.
Lee HS, Choi SI, Lee HK, et al (2002). Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol, 15, 632–40.
Leung WK, Kim JJ, Kim JG, et al (2000). Microsatellite instability in gastric intestinal metaplasia in patients with...
and without gastric cancer. Am J Pathol, 156, 537–43.
Li J-H, Shi X-Z, Lv S, et al (2005). Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J Gastroenterol, 11, 4363–6.
Lin JT, Wu MS, Shun CT, et al (1995). Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. Eur J Cancer, 31, 1879–82.
Loukola A, Eklín K, Laiho P, et al (2001). Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res, 61, 4545–9.
Mathiak M, Warneke VS, Behrens HM, et al (2017). Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: Urgent need for standardization. Appl Immunohistochem Mol Morphol, 25, 12–24.
Matsusaka K, Kaneda A, Nagae G, et al (2011). Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res, 71, 7187–97.
Modica I, Soslow RA, Black D, et al (2007). Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol, 31, 744–51.
Moskaluk CA, Rumpel CA (1998). Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma. Cancer, 83, 232–9.
Oliveira C, Seruca R, Seixas M, Sobrinho-Simões M (1998). The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different ‘target genes’: a study of the TGFβ RII, IGFII R, and BAX genes. Am J Pathol, 153, 1211–9.
Rugge M, Bersani G, Bertorelle R, et al. (2005). Microsatellite instability and gastric non-invasive neoplasia in a high risk population in Cesena, Italy. J Clin Pathol, 58, 805–10.
Samimi G, Fink D, Varki NM, et al (2000). Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res, 6, 1415–21.
Scartozzi M, Galizia E, Freddari F, et al (2004) Molecular biology of sporadic gastric cancer: Prognostic indicators and novel therapeutic approaches. Cancer Treat Rev, 30, 451–9.
Sepulveda AR, Santos AC, Yamaoka Y, et al (1999). Marked differences in the frequency of microsatellite instability in gastric cancer from different countries. Am J Gastroenterol, 94, 3034 - 8.
Shia J (2008). Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: Part I. The utility of immunohistochemistry. J Mol Diagnostics, 10, 293–300.
Shokal U, Sharma PC (2012). Implication of microsatellite instability in human gastric cancers. Indian J Med Res, 135, 599–613.
Simpson AJG, Caballero OL, Pena SDJ (2000). Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med, 7, 76–80.
Southey MC, Jenkins MA, Mead L, et al. (2005). Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol, 23, 6524–32.
Szász AM, Láneczky A, Nagy Á, et al (2016). Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget, 7, 49322–33.
Wirtz HC, Müller W, Noguchi T, et al (1998). Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res, 4, 1749–54.
Wong SS, Kim KM, Ting JC, et al (2015). Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun, 5, 1–12.
Wu MS, Lee CW, Shun CT, et al (1998). Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res, 58, 1494–7.
Zainal AO, Nor Saleha IT (2011). National Cancer Registry Report.
Zaky AH, Watari J, Taneha H, et al (2008). Clinicopathologic implications of genetic instability in intestinal-type gastric cancer and intestinal metaplasia as a precancerous lesion: Proof of field cancerization in the stomach. Am J Clin Pathol, 129, 613–21.

This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.